Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TAF15
REST API REST API
Homo sapiens
TAF15 is differentially expressed in 199 experiments: 81 organism parts: lung, prostate, ... (79 more);, 120 disease states: normal, acute myeloid leukemia, ... (118 more);, 58 cell types 244 cell lines 28 compound treatments and 61 other conditions.
Synonyms RBP56, Npl3, TAF2N, hTAFII68
Orthologs Taf15 (Rattus norvegicus)   TAF15 (Bos taurus)   Taf15 (Mus musculus)   TAF15 (Gallus gallus)   TAF15 (Danio rerio)   F1LWL0_RAT (Rattus norvegicus)   GAR1 (Saccharomyces cerevisiae)   caz (Drosophila melanogaster)   CG14718 (Drosophila melanogaster)   taf15 (Xenopus laevis)   TAF15 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, protein binding, cytoplasm, intracellular, metal ion binding, nucleic acid binding, nucleus, nucleotide binding, positive regulation of transcription, DNA-dependent, RNA binding, zinc ion binding
InterPro Term Znf_RanBP2, RRM_dom
UniProt Accession Q92804, Q86X94, F5GWQ7
Gene-Disease Assocation CHONDROSARCOMA, EXTRASKELETAL MYXOID
Search EB-eye ENSG00000172660
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-GEOD-1577, E-MTAB-24, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (31 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-62, E-MEXP-440, E-MTAB-37
MOLT4
2
E-MTAB-62, E-MTAB-37
SW480
2
E-MEXP-1014, E-GEOD-18005
UACC812
2
E-MTAB-37, E-MTAB-62
RERFLC-KJ
1
E-MTAB-62
SUDHL16
1
E-MTAB-37
238 more value(s).


Cell type

studied in E-GEOD-3920, E-GEOD-20677, E-GEOD-13909, E-GEOD-4219, E-GEOD-13987, ... (27 experiments)

Factor Value U/D Experiments
cardiac myocyte
2
E-AFMX-5, E-TABM-145
CD19+ B cells (neg. sel.)
2
E-TABM-145, E-AFMX-5
CD34+
2
E-TABM-145, E-AFMX-5
mononuclear
2
E-GEOD-13987, E-GEOD-26672
platelet
1
E-GEOD-2006
naive B cell
1
E-TABM-702
52 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-25, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, ... (39 experiments)

Factor Value U/D Experiments
breast carcinoma
2
E-TABM-276, E-GEOD-7307
colorectal adenocarcinoma
2
E-MTAB-62, E-AFMX-5
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
Crohn's disease
1
E-GEOD-3365
Wilms tumor
1
E-MTAB-37
114 more value(s).


Compound treatment

studied in E-MEXP-2449, E-GEOD-6907, E-GEOD-5824, E-GEOD-6462, E-MEXP-941, ... (17 experiments)

Factor Value U/D Experiments
glutamine
2
E-MEXP-1335, E-MEXP-941
Cxcl12
1
E-GEOD-7307
control for heregulin
1
E-GEOD-6462
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
rapamycin
1
E-GEOD-5824
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
22 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-2171, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-1140, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22148, E-TABM-147, E-GEOD-21138, E-GEOD-3013 ... (5 experiments)

Environmental stress
studied in E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-6532

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-20847, E-MEXP-2340

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-TABM-601, E-GEOD-1153, ... (7 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-7011, E-MEXP-1446, E-GEOD-22278, ... (6 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-3720, E-MEXP-2069, E-TABM-26, ... (27 experiments)

individual id
studied in E-GEOD-19519

Infection
studied in E-GEOD-2405, E-GEOD-17400

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Library source
studied in E-GEOD-19323

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-1657, E-GEOD-4600

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19246

Replicate
studied in E-GEOD-18791

RNAi
studied in E-MEXP-2115, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21574

Stimulation
studied in E-GEOD-4883, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922

Processing time: 0.321 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM